Corpus Intelligence IC Memo — PRESBYTERIAN HOSPITAL 2026-04-26 17:21 UTC
IC Memo — PRESBYTERIAN HOSPITAL
Investment Committee Memorandum | NM | 822 beds | Grade C | EBITDA uplift $102.2M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

PRESBYTERIAN HOSPITAL

CCN 320021 | BERNALILLO, NM | 822 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

PRESBYTERIAN HOSPITAL is a 822-bed large academic medical center in BERNALILLO, NM with $1.39B in net patient revenue and a -16.8% operating margin. The hospital serves a payer mix of 17.5% Medicare, 2.3% Medicaid, and 80.3% commercial.

Thesis: Undervalued. Our ML models identify $102.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -16.8% to -9.5% (+736bps).

Net Revenue HCRIS$1.39B
Current EBITDA COMPUTED$-233.8M
Operating Margin COMPUTED-16.8%
Occupancy HCRIS73.1%
Revenue / Bed COMPUTED$1.7M
Net-to-Gross HCRIS34.5%
Distress Probability ML44.1%

2. Market Context & Competitive Position

55
NM Hospitals
-2.7%
State Median Margin
379
Comparable Hospitals

NM has 55 Medicare-certified hospitals with a median operating margin of -2.7%. The target's margin of -16.8% places it below the state median. Among 379 size-comparable peers (411-1644 beds), the median margin is -4.7%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (411-1644), prioritizing same-state peers. 379 hospitals in the comp set.

HospitalStateBedsRevenueMargin
PRESBYTERIAN HOSPITAL (Target)NM822$1.39B-16.8%
ST. LUKES HOSPITALPA633$8.94B87.9%
NYU LANGONE HOSPITALSNY1618$7.24B-7.8%
STANFORD HEALTH CARECA657$6.76B3.7%
CLEVELAND CLINIC HOSPITALOH1326$6.38B-17.7%
VANDERBILT UNIVERSITY MEDICAL TN1084$5.44B-15.9%
UCSF MEDICAL CENTERCA834$5.44B-5.4%
UT MD ANDERSON CANCER CENTERTX721$4.90B-0.8%
UNIV OF MI HOSPITALS & HLTH CTMI951$4.62B-1.4%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $102.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$29.2M+210bp18mo
Cost to Collect4.5%2.5%$27.8M+200bp12mo
Denial Rate Reduction12.0%6.5%$27.5M+198bp12mo
A/R Days Reduction5200.0%3800.0%$16.9M+122bp9mo
Clean Claim Rate88.0%96.0%$889K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$29.2M
Cost to Collect
$27.8M
Denial Rate Reduction
$27.5M
A/R Days Reduction
$16.9M
Clean Claim Rate
$889K
Total EBITDA Uplift$102.2M
Current EBITDA$-233.8M
+ RCM Uplift+$102.2M
Pro Forma EBITDA$-131.6M
Current Margin-16.8%
Pro Forma Margin-9.5%
WC Released (1x)$53.3M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-359.7M$-520.0M0.00x-100.0%
Base (11x exit)10.0x11.0x$-359.7M$-688.8M0.00x-100.0%
Bull Case9.0x11.0x$-323.7M$-468.3M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-323.7M$-606.4M0.00x-100.0%
Bear Case11.0x10.0x$-395.7M$-914.3M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-395.7M$-1.13B0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 379 hospitals with 411-1644 beds
  • Same-state prioritization (n=2)
  • Comp margins: P25=-14.8% / P50=-4.7% / P75=3.3%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.